Objectives: To assess time trends of outpatient antibiotic utilization using different measures and explore their discrepancies.
Introduction
Overuse and inappropriate prescribing of antibiotics rank as the most important causes of the emergence of antibiotic resistance. 1, 2 At least 25000 deaths in Europe and 700000 deaths worldwide each year are attributed to antibiotic-resistant pathogens. 3 In the early 2000s, several countries started multifaceted awareness campaigns to promote the rational use of antibiotics. For example, in France, a country with high levels of antibiotic use, a nationwide campaign was launched in 2002 to reduce antibiotic prescription rates in the outpatient setting. A significant reduction in antibiotic prescriptions was observed after the implementation of this programme, but the effect seemed to diminish after a few years. [4] [5] [6] [7] A recent publication reported an increase in French antibiotic consumption since 2010. 4 Proper monitoring of antibiotic utilization is crucial to assess the effectiveness of such campaigns and to better define corrective actions and goals for future antibiotic stewardship programmes.
The number of prescriptions dispensed to patients may be difficult and costly to obtain, especially in low-and middle-income countries where such data are not routinely collected. To overcome these issues, the WHO in 1981 recommended assessing trends in drug utilization using the DDD, notably for the purpose of international comparisons. 8 The DDD is the assumed average maintenance dose per day for the main indication of the drug in adults. 9 Antibiotic utilization can be estimated using data on antibiotic dispensing (reimbursement or sales data) by calculating the number of DDDs per 1000 inhabitants per day (DID).
In 2004, Monnet et al. 10 reported a strong correlation between estimates of antibiotic utilization expressed in DID and number of prescriptions per 1000 inhabitants per day (PrID), in one given year (1997). However, subsequent national studies noted discrepancies between trends expressed in DID and PrID, or between DID and number of packages per 1000 inhabitants per day (PID). [11] [12] [13] [14] For example, in Belgium, outpatient antibiotic utilization increased in terms of DID, whereas it decreased based on PrID and PID over the same time period. 11 This result was confirmed in a large international study in that total outpatient antibiotic utilization increased in Europe in terms of DID, but not in PID. 15 Despite such evidence, several countries, such as France, still monitor antibiotic utilization using DID alone. The European Surveillance of Antimicrobial Consumption (ESAC) consortium has recently recommended the use of PID in addition to DID for future surveillance of antibiotic utilization, because PID seems more correlated with PrID than DID. 11, 16 Other authors have chosen to monitor standard units per 1000 inhabitants per day (SID). 17 The question remains whether DID monitoring is still appropriate and, if so, whether DID should be monitored alone, as a single indicator of antibiotic utilization, especially in settings where data on prescriptions are directly available. The present population-based study, which included both adult and child prescriptions, aimed to assess potential discrepancies between trends of outpatient antibiotic utilization expressed in PrID, DID, PID and SID using national French antibiotic sales data. Our secondary objective was to explore the potential reasons for these discrepancies.
Methods

Data sources
We used retail pharmacy sales data aggregated by month from the Suivi de la Dispensation Médicale (SDM) database of IQVIA from January 2009 to December 2016, focusing on class J01 (Antibacterials for systemic use) of the Anatomical Therapeutic Chemical (ATC) classification (version 2017) (Table S1 , available as Supplementary data at JAC Online). The SDM database contains data on drug sales from a representative sample covering 60% of retail pharmacies in metropolitan France, as previously described in detail. 6 From this sample, IQVIA projects all prescription activity, using a specific algorithm, for 100% national coverage. We extracted projected number of antibiotic prescriptions, number of packages and number of standard units (i.e. pill, capsule, ampoule, measured spoon of 5 mL, bag) contained in each package as well as dose per standard unit. For each antibiotic prescription, we extracted the following variables: patient year of birth (which provided an estimate of patient age), type of prescriber (hospital based versus office based), antibiotic molecule and ATC class. Only antibiotics given to outpatients were extracted.
We used demographic data from the French National Institute of Statistics and Economic Studies, a governmental agency that collects and publishes information about the French economy and population. 18 
Measures of antibiotic utilization
We calculated the number of standard units as the product of the number of packages times the number of standard units per package, and the number of DDDs as the product of the number of standard units times the dose per standard unit, divided by the WHO-assigned DDD. 9 We expressed antibiotic utilization data in PrID, DID, PID and SID by dividing the numbers of dispensed prescriptions, DDDs, packages and standard units by the relevant population (total, ,15 years old or 15 years old), multiplying by 1000 and then dividing by the number of days per month or per year. The number of DDDs per prescription was calculated by dividing DID by PrID.
Statistical analysis
First, we plotted yearly data (July-June years) and calculated the relative change in antibiotic utilization between the last and first year of study (2015-16 versus 2009-10), using each measure.
Second, we modelled monthly antibiotic utilization over time using a non-linear fixed-effect model, as proposed by the ESAC Project Group. 16 In this model, the intercept reflects antibiotic utilization at baseline (January 2009) and the slope reflects the trend in antibiotic utilization over time; a negative slope indicates a decrease over time, whereas a positive slope indicates an increase. We modelled seasonal patterns with a timedependent sinusoidal function, consistent with previous literature (see Supplementary Methods). 15 The parameters of the model were estimated by the least-squares method. 19 We evaluated the robustness of our findings using autoregressive integrated moving average (ARIMA) modelling. 20 Third, we modelled the evolution of the number of DDDs per prescription using the same non-linear fixed-effect model. In an exploratory analysis, we assessed the influence of four possible predictors on the number of DDDs per prescription using linear regression. The first and second predictors were the proportions of amoxicillin and amoxicillin/clavulanate prescriptions, because amoxicillin is the most prescribed antibiotic in ambulatory care, 11, 16 because physicians prescribe amoxicillin and amoxicillin/clavulanate at doses greater than the DDD (i.e. 2-3 g instead of 1 g) in line with official guidelines and product labelling 21 and because of national clinical practice guidelines issued in 2011 recommending amoxicillin as the first-line antimicrobial agent for upper respiratory tract infections. 22 The third predictor was the proportion of adult (age 15 years) prescriptions, because of the greater impact of antibiotic stewardship campaigns on paediatric prescriptions and given that prescribed doses are expected to be higher in adults than in children. 5, 7, 23, 24 The fourth predictor was the proportion of hospital prescriptions (outpatient consultations, emergency department visits and hospital discharge), because higher doses of antibiotics and/or longer treatment durations may be prescribed in this setting. 25, 26 To assess changes over time of these predictors, we used the same nonlinear fixed-effect model, relying on monthly aggregated data.
Finally, in a sensitivity analysis, we explored the impact of the DDD of amoxicillin and amoxicillin/clavulanate on trends in DID and number of DDDs per prescription applying different DDDs, from 0.5 to 3 g.
Information points with missing data on age were included in the overall assessments of antibiotic utilization, but were excluded in analyses stratified by age groups. The datasets were managed in SAS (SAS Institute, Inc., Cary, NC, USA) and statistical analyses involved use of R software (R Foundation for Statistical Computing, Vienna, Austria).
Results
Outpatient antibiotic utilization
Between January 2009 and December 2016, 299.9 million prescriptions (equivalent to 538.2 million projected prescriptions for the metropolitan French population) were collected by the SDM panel. Age data were missing for 2.5% of the projected prescriptions. 
Trends in antibiotic utilization
Based on annual utilization rates, outpatient antibiotic utilization decreased in PrID (-10%), PID (-8%) and SID (-8%) and increased in DID (!2%) ( Table 1 and Figure 1 ). Based on monthly utilization rates, outpatient antibiotic utilization significantly decreased in PrID (slope -0.004; P , 0.001), PID (slope -0.006; P , 0.01) and SID (slope -0.075; P , 0.001), although we could not reject the null hypothesis for DID (slope 0.009; P " 0.4) ( Table 2 and Figure 2) . Similar results were obtained using ARIMA modelling (data available upon request).
Number of DDDs per prescription
Based on annual utilization rates, there was an increase in the number of DDDs per prescription (!14%) and in the proportions of adult prescriptions (!4%), amoxicillin prescriptions (!34%), amoxicillin/clavulanate prescriptions (!9%) and hospital prescriptions (!31%) ( Table 1 ). The non-linear fixed-effect model based on monthly aggregated data confirmed a significant increase in the number of DDDs per prescription (slope 0.019; P , 0.001) and in the proportions of adult prescriptions (slope 0.05; P , 0.001), amoxicillin prescriptions (slope 0.11; P , 0.001), amoxicillin/clavulanate prescriptions (slope 0.02; P , 0.001) and hospital prescriptions (slope 0.03; P , 0.001) (Table S2 and Table 2 ).
In univariate analyses, the number of DDDs per prescription increased with the proportions of amoxicillin prescriptions (coefficient 0.12; P , 0.05), amoxicillin/clavulanate prescriptions (coefficient 0.45; P , 0.05), adult prescriptions (coefficient 0.13; P , 0.05) and hospital prescriptions (coefficient 0.25; P , 0.05); associations were confirmed in multivariable analyses (adjusted coefficients 0.10, 0.15, 0.07 and 0.05, respectively; all P , 0.05; adjusted R 2 0.98) ( Table 3) .
Sensitivity analysis
The time trend regression slope of DID became negative when we changed the values of DDD of amoxicillin to 1.5 g and statistically significant for values 2 g (Table S3 ). Based on annual rates, overall antibiotic utilization (DID) decreased by 2% and 5% using DDD values of 1.5 and 2.0 g for amoxicillin, respectively. The overall number of DDDs per prescription decreased to values ranging between 7.6 and 8.5 for a DDD of amoxicillin of 1.5 g and further decreased to values between 6.7 and 7.3 for a DDD of amoxicillin of 2.0 g (Table S4 ).
Discussion
We report an analysis of time trends of outpatient antibiotic utilization using different measures based on French sales data. During the period from 2009 to 2016, there was no detectable trend in DID, but a significant decrease in PrID, PID and SID. The discrepancy between DID and PrID was reflected by an increase in the number of DDDs per prescription over time, which could be explained by the proportion of amoxicillin and amoxicillin/clavulanate prescriptions, as well as by adult and hospital prescriptions. The discrepancy between DID and PrID was no longer observed when the DDD of amoxicillin was set to values 1.5 g.
Potential implications
Our findings have one main implication: DID should not be used as a single indicator of antibiotic utilization. We, rather, recommend the use of DID together with PrID for surveillance purposes. The number of DDDs per prescription is also relevant since it should reflect the duration of treatment, provided that DDDs of antibiotics match the prescribed daily doses. In our study, the overall number of DDDs per prescription was 10, which is inconsistent with external data showing that only 6% of antibiotic prescriptions are for 10 day courses in France. 4 In this case, high numbers of DDDs per prescription may reflect high prescribed doses rather than long courses of treatment.
Amoxicillin is the most prescribed antibiotic in France, accounting for one-quarter of prescriptions. The proportion of amoxicillin prescriptions increased (!34%) between 2009-10 and 2015-16. 
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We assume this results from the implementation of France's 2011 guidelines for upper respiratory tract infections, 22 which recommend high-dose amoxicillin as first-line therapy, in line with North American guidelines for managing community-acquired pneumonia and sinusitis. 27, 28 This explains the positive association between the proportion of amoxicillin prescriptions and the number of DDDs per prescription. In a sensitivity analysis, we found that, with a DDD of amoxicillin changed to 1.5 or 2 g, the trend in DID became negative and more consistent with the trend in PrID. Moreover, the proportion of formulations containing 1 g of amoxicillin per standard unit or dose was 55% over the study period, reflecting prescriptions with doses of amoxicillin much higher than the DDD ( Figure S1 ). These findings suggest that the DDD of amoxicillin is inappropriate and that it might be time to update the DDD of amoxicillin to 1.5 or 2 g, instead of 1 g.
Several previous studies have found that the French awareness campaign launched in 2002 had its greatest impact on the paediatric population. 5, 7 However, because the DDD is defined as a reference dose for adults, some authors suggested excluding paediatric data from antibiotic utilization audits based on DDDs. 29 We believe it is more relevant to retain paediatric data and analyse their effect on utilization estimates. Our findings confirm a Canadian observation of an increase in the number of DDDs per prescription over time with a concomitant decrease in the proportion of paediatric prescriptions. 14 Since the emergency department lies at the interface between the inpatient and outpatient settings, emergency department practitioners may tend to prescribe higher doses and longer courses Trinh et al.
of antibiotics to their outpatients. 25, 26 We found higher numbers of DDDs per prescription in hospital prescriptions (Table S2) , suggesting that specific studies in this setting are needed.
PrID reflects the evolution of antibiotic usage, which in turn reflects the quality of prescribing by capturing the dose and duration for which the antibiotic is prescribed. Conversely, PID, SID and DID indicate the evolution of antibiotic consumption, i.e. the raw quantity of antibiotics dispensed to patients. Measures of antibiotic usage and consumption are complementary indicators to inform policy. As found in Belgium, PID and SID seem to be better proxies for PrID than DID, provided that the numbers of packages per prescription and of standard units per package remain stable over time and across therapeutic classes. 11 Because the number of standard units per package and the amount of active substance per unit are likely to vary across countries, we recommend using PID and SID only for studying trends in antibiotic consumption at a national level. For example, in our study, one antibiotic prescription persistently corresponded to two packages being dispensed (Table S5) , whereas in Belgium one prescription corresponds to one package. 11 Moreover, PID may not be applicable in several countries in Europe and North America where community pharmacies dispense the exact number of standard units required instead of packages.
Strengths and limitations
To our knowledge, this study is the first to explore in a quantitative manner the reasons for the discrepancies observed between trends in antibiotic utilization expressed in different measures. So far, French policymakers have relied on the evolution of DID to set their priorities. This study indicates that, if ignored, discrepancies between trends in DID and PrID may produce misdirected public health messages and policies. Because of the increase in DID over the study period, the French Drug Safety Agency sent warnings to prescribers and to the public, urging them to reduce antibiotic utilization. Had they been aware that the number of prescriptions declined at the time, they may have communicated differently.
In a study including data across 31 European countries (2000-07), Bruydonckx et al. 15 found that total outpatient antibiotic utilization significantly increased in terms of DID, but not in PID. However, there were no data about prescription rates. The present study confirms the discrepancy between trends in DID and in PID at a national level and enables the reasons for such a JAC discrepancy to be identified. We also report that the same inconsistency may exist between trends in DID (!2%) and trends in PrID (-10%). Our study has several limitations. We used antibiotic sales data from the IQVIA SDM database, which relies on a representative sample of only 60% of retail pharmacies in France; selection bias may still be present in our analyses. However, our annual estimates of antibiotic utilization expressed in DID were consistent with those from the French Drug Safety Agency ( Figure S2) . 4 In our dataset, 2.5% of prescriptions had missing age data; the proportion of missing data remained stable over time and we believe it did not bias our results (Table S6 ). When modelling the number of DDDs per prescription, we could not include important predictors such as the actual prescribed dose and the duration of treatment because these variables were not available. This is a national study and our findings should be confirmed in other countries.
Conclusions
We found substantial discrepancies between the different measures of antibiotic utilization, notably between DID and PrID. Discrepancies between trends in PrID and DID in France may partly be explained by increases in the proportions of amoxicillin, amoxicillin/clavulanate, adult and hospital prescriptions over time and an inappropriate DDD for amoxicillin. We caution against using DID alone when monitoring antibiotic utilization and recommend considering monitoring both DID and PrID, as they provide different kinds of relevant information, especially when studying trends at a national level.
